Osteogenic sarcoma of the somatic soft tissues is a rare, highly lethal tumor with an average survival of 3 to 4 years and no clear histologic predictors of clinical course.
Answers are grounded in this paper and cite their sources.
Warrants guarded prognostication in rare soft tissue osteosarcoma; leaves open discovery of non-histologic prognostic markers.
Twenty-six cases of osteogenic sarcoma of the somatic soft tissue were found during a review of more than 2,100 somatic soft-tissue sarcomas in the files of the Mayo Clinic. These cases bring the total reported in the English literature through 1968 to 94. In the present series, no tumors occurred during the first two decades of life, in contrast to those primary in bone in which the peak incidence is in the second decade. Twenty-four tumors were found in the limbs and limb girdles, and two in the retroperitoneum. The spectrum of histologic patterns as described for osteogenic sarcoma in bone was applied to establish the diagnosis. Five tumors were subtyped as chondroblastic, 10 as fibroblastic, and 11 as osteoblastic; all were poorly differentiated. Sarcomas with benign osseous or chondromatous metaplasia, mixed mesenchymal sarcomas, pseudo-malignant tumors of soft parts (niyositis ossificans), and parosteal osteogenic sarcomas were excluded. In the series, 21 patients had died. Of the 5 living patients, only 2 are long-term survivors (8 and 12 years). The average survival period was between 3 and 4 years, although 3 patients died with recurrent or mctastatic disease 7, 9, and 14 years after initial treatment. No histologic difference could be detected between tumors with a rapid clinical course and those with a prolonged course.
No takes yet. Share an insight, caveat, or question.
Allan et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: